Stryker Corporation $SYK Shares Purchased by Wealthcare Advisory Partners LLC

Wealthcare Advisory Partners LLC raised its position in Stryker Corporation (NYSE:SYK) by 265.2% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 9,328 shares of the medical technology company’s stock after purchasing an additional 6,774 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Stryker were worth $3,278,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of SYK. Alliancebernstein L.P. boosted its holdings in shares of Stryker by 307.6% during the 2nd quarter. Alliancebernstein L.P. now owns 5,596,508 shares of the medical technology company’s stock worth $2,214,146,000 after purchasing an additional 4,223,366 shares during the last quarter. Corient Private Wealth LLC increased its holdings in shares of Stryker by 104.4% in the second quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock valued at $887,525,000 after purchasing an additional 1,146,998 shares during the last quarter. Strive Asset Management LLC purchased a new position in Stryker during the third quarter worth approximately $227,389,000. Credit Agricole S A acquired a new position in Stryker during the third quarter worth $194,045,000. Finally, APG Asset Management N.V. boosted its stake in Stryker by 47.6% during the third quarter. APG Asset Management N.V. now owns 943,648 shares of the medical technology company’s stock worth $348,838,000 after buying an additional 304,203 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, Director Ronda E. Stryker sold 250,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 4th. The shares were sold at an average price of $362.92, for a total value of $90,730,000.00. Following the completion of the transaction, the director owned 2,457,331 shares of the company’s stock, valued at approximately $891,814,566.52. This trade represents a 9.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 5.20% of the company’s stock.

Stryker Stock Performance

Shares of SYK stock opened at $327.49 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.21 and a current ratio of 1.89. The firm has a market cap of $125.42 billion, a P/E ratio of 38.99, a P/E/G ratio of 1.91 and a beta of 0.85. The firm’s 50 day moving average price is $360.17 and its 200-day moving average price is $363.56. Stryker Corporation has a one year low of $324.93 and a one year high of $404.87.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, January 29th. The medical technology company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.40 by $0.07. Stryker had a net margin of 12.92% and a return on equity of 24.41%. The firm had revenue of $7.17 billion during the quarter, compared to the consensus estimate of $7.12 billion. During the same quarter last year, the firm earned $4.01 EPS. The firm’s revenue for the quarter was up 11.4% on a year-over-year basis. As a group, equities research analysts predict that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be given a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, March 31st. Stryker’s payout ratio is currently 41.90%.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. Sanford C. Bernstein raised their target price on Stryker from $450.00 to $465.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. Needham & Company LLC lifted their target price on shares of Stryker from $448.00 to $454.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Citizens Jmp raised shares of Stryker from a “market perform” rating to an “outperform” rating and set a $440.00 price target for the company in a research note on Friday, December 19th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Stryker in a research report on Monday, December 22nd. Finally, BTIG Research increased their price objective on Stryker from $410.00 to $412.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Fourteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Stryker currently has an average rating of “Moderate Buy” and a consensus target price of $427.50.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.